Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review

Yu, Ping; He, Xiangyi; Lu, Fei; Li, Ling; Song, Huahua; Bian, Xiaolan

doi:10.21037/jtd-22-897

Cited by 9 publications

(8 citation statements)

References 97 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is a leading cause of cancer-related deaths worldwide (1). Non-small cell lung cancer (NSCLC) accounts for >75% of all cases of lung cancer and can be further classified into 3 subtypes; that is, adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (2)(3)(4)(5). A number of studies have successfully applied molecular-targeted therapeutic agents and d e m o n s t r a t e d t h e i r s u p e r i o r i t y t o c o n v e n t i o n a l chemotherapy in treating NSCLC (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Lin¹,

Long²,

Chen³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background This study sought to examine the expression and mutation status of fibroblast growth factor receptor 3 (FGFR3) in non-small cell lung cancer (NSCLC) tissues and explore the prognostic potential of FGFR3 in NSCLC. Methods Immunohistochemistry (IHC) was used to evaluate the FGFR3 protein expression of 116 NSCLC tissues. Sanger sequencing was used to examine the mutation status of exons 7, 10, and 15 in FGFR3. A Kaplan‑Meier survival analysis was conducted to evaluate the association between the expression level of FGFR3 and the overall survival (OS) and disease-free survival (DFS) of NSCLC patients. Univariate and multivariate Cox analyses were conducted to examine the association between the risk score and clinical features. Results FGFR3 was immunoreactive in 26 of the 86 NSCLC cases. Further, FGFR3 was positively expressed in 84.6% of the lung adenocarcinoma (AC) cases and 15.4% of the lung squamous cell carcinoma (SCC) cases. FGFR3 mutations were detected in 2 NSCLC patients (2/72, 2.8%), who both harbored the T450M mutation, a novel mutation in exon 10 of FGFR3. In NSCLC, a high expression of FGFR3 was positively correlated with gender, smoking, histology type, T stage, and the epidermal growth factor receptor (EGFR) mutation (P<0.05). FGFR3 expression was also correlated with better OS and DFS. The multivariate analysis revealed that FGFR3 served as an independent prognostic factor (P=0.024) for the OS of NSCLC patients. Conclusions This study showed that FGFR3 was highly expressed in NSCLC tissues, and the frequency rate for the FGFR3 mutation at T450 M in NSCLC tissues was low. The survival analysis suggested that FGFR3 may be a useful prognostic biomarker in NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

Lin¹,

Long²,

Chen³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…The 5‐year overall survival (OS) rate of advanced NSCLC has greatly improved due to the targeted therapies and immune checkpoint inhibitors 2,3 . However, these agents preferentially benefit patients with LUAD, 5 and the current OS of LUSC remains 20%–30% less than that of LUAD 6–8 . These differences in available therapeutic strategies and clinical outcomes result from different molecular patterns according to tumor genomic aberration or transcript alterations 4 .…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“… 2 , 3 However, these agents preferentially benefit patients with LUAD, 5 and the current OS of LUSC remains 20%–30% less than that of LUAD. 6 , 7 , 8 These differences in available therapeutic strategies and clinical outcomes result from different molecular patterns according to tumor genomic aberration or transcript alterations. 4 Hence, elucidating the molecular mechanisms underlying tumorigenesis and progression might be conducive to developing more effective therapeutic targets for LUSC.…”

Section: Introductionmentioning

confidence: 99%

“…Noncoding RNAs (ncRNAs), especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), contribute to various biological processes in cancer tumorigenesis and progression. 5 , 6 LncRNA with a length >200 nucleotides may be involved in more diverse and complex mechanisms for regulating the biogenetic process because of the longer sequences and more complex spatial structures compared with small RNAs. 7 , 8 LncRNAs interact with DNAs, RNAs, and proteins to participate in numerous physiological and pathological processes at the transcriptional, translational, and epigenetic levels and other mechanisms such as chromatin remodeling, cell cycle regulation, splicing regulation, mRNA degradation, and translational regulation.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

LINC02323 facilitates development of lung squamous cell carcinoma by miRNA sponge and RBP dysregulation and links to poor prognosis

Tsai

Huang

et al. 2022

Thoracic Cancer

View full text Add to dashboard Cite

Background The poor outcome of patients with lung squamous cell carcinoma (LUSC) highlights the importance of the identification of novel effective prognostic markers and therapeutic targets. Long noncoding RNAs (lncRNAs) have generally been considered to serve important roles in tumorigenesis and the development of various types of cancer, including LUSC. Methods Here, we aimed to investigate the role of LINC02323 in LUSC and its potential mechanisms by performing comprehensive bioinformatic analyses. Results LINC02323 was elevated and positively associated with unfavorable prognosis of LUSC patients. LINC02323 exerted oncogenic function by competitively binding to miR‐1343‐3p and miR‐6783‐3p, thereby upregulating L1CAM expression. Indeed, we also determined that LINC02323 could interact with the RNA‐binding protein DDX3X, which regulates various stages of RNA expression and processing. Conclusion Taken together, we identified that LINC02323 and its indirect target L1CAM can act as novel biomarkers for determining the prognosis of patients with LUSC and thus deserves further study.

show abstract

Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy

Kadian,

Verma,

Lohani

et al. 2024

Mol Cell Biochem

View full text Add to dashboard Cite

Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review

Cited by 9 publications

References 97 publications

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

LINC02323 facilitates development of lung squamous cell carcinoma by miRNA sponge and RBP dysregulation and links to poor prognosis

Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy

Contact Info

Product

Resources

About